Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/138851
Title: The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells
Authors: Pillozzi, Serena
D'Amico, Massimo
Bartoli, Gianluca
Gasparoli, Luca
Petroni, Giulia
Crociani, Olivia
Marzo, Tiziano
Guerriero, Angela
Messori, Luigi
Severi, Mirko
Udisti, Roberto
Wulff, Heike
Chandy, Kanianthara George
Becchetti, Andrea
Arcangeli, Annarosa
Keywords: Science::Medicine
Issue Date: 2018
Source: Pillozzi, S., D'Amico, M., Bartoli, G., Gasparoli, L., Petroni, G., Crociani, O., . . . Arcangeli, A. (2018). The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells. British Journal of Cancer, 118(2), 200-212. doi:10.1038/bjc.2017.392
Journal: British Journal of Cancer
Abstract: Background: Platinum-based drugs such as Cisplatin are commonly employed for cancer treatment. Despite an initial therapeutic response, Cisplatin treatment often results in the development of chemoresistance. To identify novel approaches to overcome Cisplatin resistance, we tested Cisplatin in combination with K+ channel modulators on colorectal cancer (CRC) cells. Methods: The functional expression of Ca2+-activated (KCa3.1, also known as KCNN4) and voltage-dependent (Kv11.1, also known as KCNH2 or hERG1) K+ channels was determined in two CRC cell lines (HCT-116 and HCT-8) by molecular and electrophysiological techniques. Cisplatin and several K+ channel modulators were tested in vitro for their action on K+ currents, cell vitality, apoptosis, cell cycle, proliferation, intracellular signalling and Platinum uptake. These effects were also analysed in a mouse model mimicking Cisplatin resistance. Results: Cisplatin-resistant CRC cells expressed higher levels of KCa3.1 and Kv11.1 channels, compared with Cisplatin-sensitive CRC cells. In resistant cells, KCa3.1 activators (SKA-31) and Kv11.1 inhibitors (E4031) had a synergistic action with Cisplatin in triggering apoptosis and inhibiting proliferation. The effect was maximal when KCa3.1 activation and Kv11.1 inhibition were combined. In fact, similar results were produced by Riluzole, which is able to both activate KCa3.1 and inhibit Kv11.1. Cisplatin uptake into resistant cells depended on KCa3.1 channel activity, as it was potentiated by KCa3.1 activators. Kv11.1 blockade led to increased KCa3.1 expression and thereby stimulated Cisplatin uptake. Finally, the combined administration of a KCa3.1 activator and a Kv11.1 inhibitor also overcame Cisplatin resistance in vivo. Conclusions: As Riluzole, an activator of KCa3.1 and inhibitor of Kv11.1 channels, is in clinical use, our results suggest that this compound may be useful in the clinic to improve Cisplatin efficacy and overcome Cisplatin resistance in CRC.
URI: https://hdl.handle.net/10356/138851
ISSN: 0007-0920
DOI: 10.1038/bjc.2017.392
Rights: © 2018 Cancer Research UK. All rights reserved. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons AttributionNonCommercial-Share Alike 4.0 Unported License.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
bjc2017392.pdf1.11 MBAdobe PDFThumbnail
View/Open

SCOPUSTM   
Citations 10

47
Updated on Jan 20, 2023

Web of ScienceTM
Citations 10

41
Updated on Jan 23, 2023

Page view(s)

179
Updated on Jan 27, 2023

Download(s) 50

32
Updated on Jan 27, 2023

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.